By Paul Ogendi
In 2012, the Kenyan High Court issued a landmark judgment in favour of access to affordable medicines discussed on the IP Kenya blog here. In a bold manner, the decision further recommended a review of sections 2, 32, and 34 of the 2008 Kenyan Anti-Counterfeit Act. The process of reviewing the legislation began, at least publicly, sometimes in 2013 after a group of access to medicines actors began making inquiries about this process. The group made several visits to the Anti-Counterfeit Agency (ACA) and the Office of the Attorney General. The group later got hold of some proposed amendments to the legislation that had been compiled over the years by the ACA. It was clear from the draft in circulation that the decision by the High Court had not been sufficiently factored in.